Parviz Salehi, MD
Surgery · Reseda, CANPI 1932124328
Payments from drug & device makers
Across 61 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$185
- Bayer$137
- Novartis$121
- Merck$109
- Puma Biotechnology, Inc.$81
- Lilly USA, LLC$80
- plus $645 from 19 others
What the payments were for
- Food & beverage$1,360100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Karyopharm Therapeutics Inc. | 7 | $185 |
| Bayer | 8 | $137 |
| Novartis | 5 | $121 |
| Merck | 4 | $109 |
| Puma Biotechnology, Inc. | 4 | $81 |
| Lilly USA, LLC | 4 | $80 |
| Taiho Oncology, Inc. | 3 | $72 |
| Johnson & Johnson(2 entities) | 3 | $72 |
| Array Biopharma Inc | 3 | $70 |
| Amgen | 3 | $63 |
| Ipsen Biopharmaceuticals, Inc | 2 | $46 |
| Seagen Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Coherus Oncology, Inc. | 1 | $29 |
| Acell, Inc. | 1 | $27 |
| Blue Earth Diagnostics | 1 | $27 |
| Incyte Corporation | 1 | $24 |
| Stemline Therapeutics Inc. | 1 | $23 |
| CTI Biopharma Corp. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| G1 Therapeutics, Inc. | 1 | $19 |
| Epizyme, Inc. | 1 | $18 |
| Iovance Biotherapeutics, Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Morphosys, US Inc. | 1 | $16 |
How this compares
$1,360 in reported general payments places this provider in the 45th percentile of 2,363 surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $3,514 |
| EdarbiAzilsartan Medoxomil | 12 | $3,001 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,247 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $767 |
| Gabapentin | 18 | $470 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $234 |
| Ondansetron OdtOndansetron | 12 | $231 |
| Amlodipine Besylate | 13 | $207 |
| Lorazepam | 16 | $172 |
| Metoprolol Succinate | 27 | $157 |
| Lisinopril | 11 | $148 |
| Rosuvastatin Calcium | 28 | $85 |
| Fluticasone Propionate | 14 | $81 |
| Celecoxib | 13 | $65 |
| Solifenacin Succinate | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Other surgery in Reseda
- Timothy ChuterSan Francisco$8.9M
- Peter StockSan Francisco$6.5M
- Santiago HorganSan Diego$2.8M
- Kenneth DeckLaguna Hills$2.4M
- Daniel RiskinSan Jose$2.2M
- Michael DemeureNewport Beach$1.7M
- Rock LiuHayward$1.6M
- David LouriePasadena$1.4M
- Andrea PakulaThousand Oaks$1.4M
- Siew-Ming LeeFresno$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.